ストックスクリーナーアプリを入手
0.46
0.65%
-0.003
アフターアワーズ：
.42
-0.04
-8.70%
前日終値:
$0.463
開ける：
$0.45
24時間の取引高:
94,115
Relative Volume:
0.02
時価総額：
$13.05M
収益：
-
当期純損益:
$-4.23M
株価収益率:
-3.081
EPS:
-0.1493
ネットキャッシュフロー:
$-10.48M
1週間 パフォーマンス:
+3.60%
1か月 パフォーマンス:
+19.79%
6か月 パフォーマンス:
-31.13%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.45
$0.4753
1週間の範囲:
$0.4336
$0.4999
52週間の値動き範囲:
$0.262
$9.1796
Curanex Pharmaceuticals Inc Stock (CURX) Company Profile
Compare CURX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CURX
Curanex Pharmaceuticals Inc
|
0.46 | 13.13M | 0 | -4.23M | -10.48M | -0.1493 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Curanex Pharmaceuticals Inc (CURX) 最新ニュース
These stocks are moving in today's pre-market session - ChartMill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Exclusive: Penny stock Curanex expands cachexia focus backed by patient recovery narratives - MSN
EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases - MSN
Curanex Pharmaceuticals Inc (CURX) stock price, news, quote and history - Yahoo Finance Singapore
Curanex Pharmaceuticals Inc (CURX) Latest Stock News & Headlines - Yahoo Finance
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline - The Manila Times
Curanex Pharmaceuticals Reports Positive Patient Outcomes in Advanced Cancer and Critical Illness Cases Following Use of Lead Product - Quiver Quantitative
Five critically ill patient accounts inform Curanex's cachexia focus - Stock Titan
EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care - The Manila Times
Curanex Pharmaceuticals Highlights Patient Case Supporting Phyto-N's Potential in Cancer Cachexia Treatment - Quiver Quantitative
One cancer patient kept working 2+ years in Curanex Phyto-N case - Stock Titan
EXCLUSIVE: Curanex Highlights Case Study Supporting Cachexia Focus In Oncology Strategy - Benzinga
Top Curanex Pharmaceuticals (CURX) Competitors 2026 - MarketBeat
Curanex Pharmaceuticals Inc (CURX) latest stock news and headlines - Yahoo Finance Singapore
Curanex Pharmaceuticals Inc (CURX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Curanex adds cancer cachexia to drug development pipeline By Investing.com - Investing.com India
Curanex adds cancer cachexia to drug development pipeline - Investing.com
Curanex Pharmaceuticals Expands Drug Development Pipeline - TradingView — Track All Markets
Curanex Adds Cancer Cachexia to Core Drug Pipeline - TipRanks
Curanex (Nasdaq: CURX) targets cancer cachexia in expanded pipeline - Stock Titan
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company - The Manila Times
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company - 富途牛牛
Curanex Pharmaceuticals and Phyto-N: Botanical Drug Development for Inflammatory Diseases, COVID-19, Diabetes, NAFLD, and Gout 33 - Minichart
Curanex Advances Phyto-N Toward IND Submission in 2026 Annual Report - National Today
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission - Bitget
CURX: IPO proceeds fund R&D for Phyto-N; no revenue, $4.2M net loss, and internal control weaknesses - TradingView
Curanex Pharmaceuticals Inc Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Curanex Pharmaceuticals (NASDAQ: CURX) outlines multi-disease Phyto-N drug strategy - Stock Titan
Curanex Pharmaceuticals Advances Key Milestones in Manufacturing, Toxicology, and Regulatory Strategy for Phyto-N Development - Quiver Quantitative
Ulcerative colitis drug candidate stays on track for late-2026 filing - Stock Titan
CURX Price Today: Curanex Pharmaceuticals Inc. Stock Price, Quote & Chart - MEXC
What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours - MSN
Stock List: Research Stocks from Around the World - GuruFocus
CURANEX PHARMACEUTICALS INC (CURX) Fundamental Analysis & Valuation - chartmill.com
CURX Should I Buy - Intellectia AI
Nasdaq tumbles over 350 points; US initial jobless claims increase - MSN
Curanex Pharmaceuticals IncTargets Ind Submission For Phyto-N In Q4 2026 - TradingView
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission - Yahoo Finance
Curanex adds two pharmaceutical veterans to advisory board By Investing.com - Investing.com Nigeria
Curanex adds two advisors to scientific board ahead of IND filing By Investing.com - Investing.com India
Curanex adds two advisors to scientific board ahead of IND filing - Investing.com Australia
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers - Bitget
TB and COVID scientists join Curanex board to steer 2026 trial plans - Stock Titan
Curanex adds two pharmaceutical veterans to advisory board - Investing.com India
Curanex Pharmaceuticals Inc (CURX) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):